Technology Diffusion, Health Outcomes, and Healthcare Expenditures
技术扩散、健康成果和医疗支出
基本信息
- 批准号:8738583
- 负责人:
- 金额:$ 76.74万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-09-30 至 2018-06-30
- 项目状态:已结题
- 来源:
- 关键词:AdoptedAdverse effectsAgeAmputationAnticoagulantsAntidiabetic DrugsAreaAtrial FibrillationBackBedsBeliefBlood GlucoseBlood VesselsCardiacCardiovascular DiseasesCarotid EndarterectomyCategoriesCharacteristicsClinicalCross-Sectional StudiesDataDatabasesDeep Vein ThrombosisDiffuseDiffusionDropsEthnic groupExhibitsExpenditureFee-for-Service PlansGlycosylated hemoglobin AGrowthHealthHealth Care CostsHealth PersonnelHealthcareHemoglobinHospitalsImmunoglobulinsImplantable DefibrillatorsIndividualInfusion proceduresIntensive Care UnitsLinkMarketingMasksMeasuresMedicalMedicareMedicare claimMonitorNeuropathyOperative Surgical ProceduresOutcomePatient SelectionPatientsPatternPharmaceutical PreparationsPhysiciansPopulationProcessProviderPublicationsQuality of CareRaceRegistriesResearchResidenciesRetinal DiseasesRiskSocial NetworkSpeedStentsStructureSubgroupSystemTechnologyTestingVariantadverse outcomebed capacityblood glucose regulationcardiovascular risk factordata registrydiabeticdiabetic patienteffective therapyexperiencefallsillegal behaviormedical schoolsmedical specialtiesorganizational structurepublic health relevancerandomized trialrapid growthrosiglitazonesocial
项目摘要
DESCRIPTION: In previous research wide variations have been found in both healthcare spending and in health outcomes, with little correlation between the two. These studies were limited to cross-sectional analysis, and tell little about the dynamic process by which these patterns arise. One hypothesis is that variation across regions in rates of technology diffusion, whether for highly effective treatments (with a large impact on health outcomes) or for expensive treatments with unknown value (with a large impact on expenditures), can explain the observed cross-sectional patterns of spending and outcomes. In this proposal, Aim 1 seeks to better understand the diffusion of highly effective healthcare such as hemoglobin A1C (HbA1c) tests for blood glucose control among diabetic patients. Using the national Doximity database on every physician in the U.S., along with information about physician-hospital networks (PHN) and physician social networks, the research team will test why HbA1c diffused so rapidly (and among all racial and ethnic groups) in some areas but not others. They will also test whether more rapid diffusion of HbA1c reduced rates of neuropathy, retinopathy, and amputation. Aim 2 focuses on the diffusion of generally beneficial treatments but where the treatment can actually harm specific types of patients. Two examples are considered: the rapid growth in implantable cardioverter defibrillators (ICDs), and the growth in new and expensive anticoagulants - dabigatran, apixaban and rivaroxaban. Aim 3 studies the opposite of diffusion - "exnovation" or a retreat from use - to ask how physician-hospital networks and regions scaled back on treatments newly found to have poor value for subgroups of patients. The proposal considers two specific treatments: the sharp reduction in carotid endarterectomy (both surgery and stents), and the decline in the use of Rosiglitazone (Avandia), an anti-diabetic drug, following a 2007 publication demonstrating serious cardiovascular risks. In these cases, the most effective exnovation patterns should experience the largest drop in use for the less appropriate patients. Aim 4 examines the diffusion of treatments with unknown or even adverse consequences, such as the rapid growth in some regions (but not others) in ICU bed capacity. The research team will study the network and diffusion patterns for "extramedical" treatments - illegal behavior motivated by profit and with no benefit for patients, with one example being the rise and fall of immunoglobulin infusions in 2002-2005. Finally, the research group will use results from these four aims to return to the central hypothesis: can observed differences in treatment-specific diffusion explain observed patterns in regional variations in health outcomes and spending?
产品说明:在以前的研究中,发现医疗保健支出和健康结果存在很大差异,两者之间几乎没有相关性。这些研究仅限于横截面分析,并告诉这些模式出现的动态过程很少。一个假设是,技术扩散率在各区域的差异,无论是高效治疗(对健康结果有很大影响)还是价值未知的昂贵治疗(对支出有很大影响),都可以解释观察到的支出和结果的横截面模式。在该提案中,目标1旨在更好地了解用于糖尿病患者血糖控制的血红蛋白A1 C(HbA 1c)测试等高效医疗保健的传播。利用美国所有医生的国家Doximity数据库,沿着关于医生-医院网络(PHN)和医生社交网络的信息,研究小组将测试为什么HbA 1c在某些地区(以及所有种族和民族群体)传播如此迅速,而不是其他地区。他们还将测试HbA 1c的快速扩散是否会降低神经病变、视网膜病变和截肢的发生率。目标2侧重于传播一般有益的治疗方法,但这种治疗方法实际上可能会伤害特定类型的患者。考虑两个例子:植入式心律转复除颤器(ICD)的快速增长,以及新型和昂贵的抗凝剂(达比加群、阿哌沙班和利伐沙班)的增长。目标3研究了扩散的反面--“扩张”或从使用中撤退--以询问医生-医院网络和地区如何缩减新发现的对患者亚组价值不高的治疗。该提案考虑了两种具体的治疗方法:颈动脉内膜切除术(手术和支架)的急剧减少,以及在2007年发表的一篇文章显示严重的心血管风险后,抗糖尿病药物罗格列酮(文迪雅)的使用减少。在这些情况下,最有效的外展模式应该经历最大的下降,在使用不太合适的患者。目标4研究了具有未知甚至不良后果的治疗的扩散,例如某些地区(但不是其他地区)ICU床位容量的快速增长。该研究小组将研究“医疗外”治疗的网络和扩散模式--受利润驱使的非法行为,对病人没有好处,其中一个例子是2002-2005年免疫球蛋白输注的兴衰。最后,研究小组将利用这四个目标的结果回到中心假设:观察到的治疗特异性扩散的差异能否解释观察到的健康结果和支出的区域差异模式?
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JONATHAN S SKINNER其他文献
JONATHAN S SKINNER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JONATHAN S SKINNER', 18)}}的其他基金
Technology Diffusion, Health Outcomes, and Healthcare Expenditures
技术扩散、健康成果和医疗支出
- 批准号:
9111769 - 财政年份:2013
- 资助金额:
$ 76.74万 - 项目类别:
Technology Diffusion, Health Outcomes, and Healthcare Expenditures
技术扩散、健康成果和医疗支出
- 批准号:
8628306 - 财政年份:2013
- 资助金额:
$ 76.74万 - 项目类别:
Technology Diffusion, Health Outcomes, and Healthcare Expenditures
技术扩散、健康成果和医疗支出
- 批准号:
9555093 - 财政年份:2013
- 资助金额:
$ 76.74万 - 项目类别:
Causes and Consequences of Variation in Public and Private Payment Rates
公共和私人支付率变化的原因和后果
- 批准号:
10433840 - 财政年份:2001
- 资助金额:
$ 76.74万 - 项目类别:
Causes and Consequences of Health Care Intensity
医疗保健强度的原因和后果
- 批准号:
6637832 - 财政年份:2001
- 资助金额:
$ 76.74万 - 项目类别:
Causes and Consequences of Health Care Intensity
医疗保健强度的原因和后果
- 批准号:
6936452 - 财政年份:2001
- 资助金额:
$ 76.74万 - 项目类别:
Causes and Consequences of Health Care Intensity
医疗保健强度的原因和后果
- 批准号:
6533935 - 财政年份:2001
- 资助金额:
$ 76.74万 - 项目类别:
EFFICIENCY OF PRESCRIPTION DRUG USE IN THE MEDICARE POPULATION
医疗保险人群中处方药的使用效率
- 批准号:
8461340 - 财政年份:2001
- 资助金额:
$ 76.74万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 76.74万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 76.74万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 76.74万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 76.74万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 76.74万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 76.74万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 76.74万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 76.74万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 76.74万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 76.74万 - 项目类别:
Discovery Grants Program - Individual